Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
Stocks · News reference
8-K filing — Mirum Pharmaceuticals, Inc. (MIRM)
Filed: 2026-09-08 AccNo: 0001759425-26-000047 Size: 143 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.